Results 91 to 100 of about 209,011 (190)

HIV protease inhibitors block parasite signal peptide peptidases and prevent growth of Babesia microti parasites in erythrocytes. [PDF]

Biochem Biophys Res Commun, 2019
Schwake C, Baldwin MR, Bachovchin W, Hegde S, Schiemer J, Okure C, Levin AE, Vannier E, Hanada T, Chishti AH.   +9 more
europepmc   +1 more source

HIV protease inhibitors block the zinc metalloproteinase ZMPSTE24 and lead to an accumulation of prelamin A in cells

Proceedings of the National Academy of Sciences of the United States of America, 2007
Catherine Coffinier, Sarah E Hudon, Emily A. Farber, Sandy Chang, C. Hrycyna, S. Young, L. Fong   +6 more
semanticscholar   +1 more source

Some HIV protease inhibitors alter lamin A/C maturation and stability, SREBP-1 nuclear localization and adipocyte differentiation

AIDS (London), 2003
M. Caron, M. Auclair, H. Sterlingot, M. Kornprobst, J. Capeau   +4 more
semanticscholar   +1 more source

Kinetic and thermodynamic characterisation of HIV-protease inhibitors against E35D↑G↑S mutant in the South African HIV-1 subtype C protease. [PDF]

J Enzyme Inhib Med Chem, 2019
Maseko S, Padayachee E, Maphumulo S, Govender T, Sayed Y, Maguire G, Lin J, Naicker T, Baijnath S, Gerhardus KH.   +9 more
europepmc   +1 more source

The effects of HIV protease inhibitors atazanavir and lopinavir/ritonavir on insulin sensitivity in HIV-seronegative healthy adults

AIDS (London), 2004
Mustafa A. Noor, R. Parker, E. O'Mara, D. Grasela, A. Currie, S. Hodder, F. Fiedorek, D. Haas   +7 more
semanticscholar   +1 more source

HIV protease inhibitors promote atherosclerotic lesion formation independent of dyslipidemia by increasing CD36-dependent cholesteryl ester accumulation in macrophages.

Journal of Clinical Investigation, 2003
James L. Dressman, J. Kincer, Sergey V. Matveev, Ling Guo, R. Greenberg, T. Guerin, David G. Meade, Xiang-An Li, Weifei Zhu, Annette M. Uittenbogaard, M. Wilson, E. Smart   +11 more
semanticscholar   +1 more source

HIV protease genotype and viral sensitivity to HIV protease inhibitors following saquinavir therapy

AIDS (London), 1998
C. Craig, E. Race, J. Sheldon, L. Whittaker, Susan M. Gilbert, Alec R. Moffatt, J. Rose, S. Dissanayeke, G. Chirn, I. Duncan, N. Cammack   +10 more
semanticscholar   +1 more source

HIV protease inhibitors saquinavir and nelfinavir are potent inhibitors of cathepsin L activity: A potential treatment for COVID-19 patients

, 2020
Montenegro MF, Al-Abed Y, He M, Tracey KJ, Billiar TR.   +4 more
europepmc   +1 more source

Pharmacokinetic Interactions between the Hepatitis C Virus Inhibitors Elbasvir and Grazoprevir and HIV Protease Inhibitors Ritonavir, Atazanavir, Lopinavir, and Darunavir in Healthy Volunteers. [PDF]

Antimicrob Agents Chemother, 2019
Feng HP, Caro L, Fandozzi C, Chu X, Guo Z, Talaty J, Panebianco D, Dunnington K, Du L, Hanley WD, Fraser IP, Mitselos A, Denef JF, De Lepeleire I, de Hoon JN, Vandermeulen C, Marshall WL, Jumes P, Huang X, Martinho M, Valesky R, Butterton JR, Iwamoto M, Yeh WW.   +23 more
europepmc   +1 more source

Differences in the intracellular accumulation of HIV protease inhibitors in vitro and the effect of active transport

AIDS (London), 2001
K. Jones, P. Hoggard, S. D. Sales, S. Khoo, R. Davey, D. Back   +5 more
semanticscholar   +1 more source